Osteosclerotic bone disease in metastatic prostate cancer is associated with excess intralesional IGFBP-3 proteolysis
Smith, G.L.; Doherty, A.P.; Christmas, T.J.; Epstein, R.J.
Journal of Urology 159(5 Suppl): 12
1998
ISSN/ISBN: 0022-5347
Accession: 032672724
PDF emailed within 1 workday: $29.90
Related References
Degraff, D.J.; Aguiar, A.A.; Sikes, R.A. 2009: Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions American Journal of Translational Research 1(2): 115-130Smith, G.L.; Doherty, A.P.; Christmas, T.J.; Hanham, I.W.; Mitchell, H.; Epstein, R.J. 1999: Tissue expression of IGFBP-3 and the effect of treatment on serum IGFBP-3 in metastatic prostate cancer Journal of Urology 161(4 Suppl): 59
Barrass, B.J.R.; Lai, T.; Perks, C.M.; Persad, R.A.; Holly, J.M. 2004: IGFBP-3 inhibits cellular migration and adhesion in androgen resistant prostate cancer Implications for metastatic spread and disease progression Growth Hormone and IGF Research 14(2): 154
Gomes, R.R.; Buttke, P.; Paul, E.M.; Sikes, R.A. 2009: Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation Clinical and Experimental Metastasis 26(7): 641-651
Rentsch, C.A.; Cecchini, M.G.; Thalmann, G.N. 2009: Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer Swiss Medical Weekly 139(15-16): 220-225
Koistinen, H.; Paju, A.; Koistinen, R.; Finne, P.; Lövgren, J.; Wu, P.; Seppälä, M.; Stenman, U-Håkan. 2002: Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3 Prostate 50(2): 112-118
Baciuchka, M.; Remacle-Bonnet, M.; Garrouste, F.; Favre, R.; Sastre, B.; Pommier, G. 1998: Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: Possible association with the metastatic potential of the tumor International Journal of Cancer 79(5): 460-467
Schmid, C.; Rutishauser, J.; Schläpfer, I.; Froesch, E.R.; Zapf, J. 1991: Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: control of IGF signalling to bone cells by IGFBP-3-specific proteolysis? Biochemical and Biophysical Research Communications 179(1): 579-585
Kulshrestha, R.K.; Vinjamuri, S.; England, A.; Nightingale, J.; Hogg, P. 2016: The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer Journal of Nuclear Medicine Technology 44(4): 217-222
Bitossi, R.; Berruti, A.; Gorzegno, G.; Tucci, M.; Mosca Frezet, M.; Torta, M.; Dogliotti, L.; Angeli, A. 1998: Bone turnover markers and serum PSA in bone metastatic prostate cancer patients with hormone refractory disease Tumor Biology 19(Suppl 2): 19
Gourmelen, M.; Lalou, C.; Perin, L.; Cabrol, S.; Binoux, M. 1993: Excess IGFBP-3 proteolysis is partly responsible for the accelerated growth in constitutionally tall children Pediatric Research 33(5 Suppl): S46
Fu, Z.; Dozmorov, I.M.; Keller, E.T. 2002: Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells Prostate 51(1): 10-20
Sarveswaran, S.; Ghosh, R.; Morisetty, S.; Ghosh, J. 2015: MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer Plos one 10(4): E0122805
Messiou, C.; Cook, G.; Reid, A.H.M.; Attard, G.; Dearnaley, D.; de Bono, J.S.; de Souza, N.M. 2011: The CT flare response of metastatic bone disease in prostate cancer Acta Radiologica 52(5): 557-561
Brundage, M.D.; Crook, J.M.; Lukka, H. 1998: Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group Cancer Prevention and Control: Cpc 2(2): 79-87